In the development of functional foods and pharmaceuticals, probiotic bacteria are used. They serve a vital function in human health promotion and maintenance. Probiotic strains must be present in a viable state at a reasonable level throughout the product's shelf life till ingestion in order to offer health benefits and retain high viability throughout the gastrointestinal tract. pH, post-acidification during product fermentation, hydrogen peroxide generation, and storage temperatures all have an impact on probiotic viability in products. Providing probiotic live cells with a physical barrier to protect them from harmful conditions is a method that is now gaining a lot of attention. PET (Probiotic encapsulation technology) is an intriguing branch of biopharmacy that has exploded in popularity over the last ten years. A variety of microorganisms have been immobilised within semipermeable and biocompatible surfaces that control cell distribution using this approach.
Title : Results from a cross-sectional observational study examining irritable bowel syndrome patients six months after finishing their participation in the ViIBS trial
Jacek Piatek, Calisia University, Poland
Title : Gut microbiome as a driver of healthy ageing
Thi Thu Hao Van, RMIT University, Australia
Title : Treating irritable bowel syndrome patients with a balanced multi-strain synbiotic–results from a multi-center, randomized, double-blind, placebo-controlled clinical trial (the ViIBS trial)
Henning Sommermeyer, Calisia University, Poland
Title : Molecular mechanisms underlying the anti-atherogenic actions of probiotics
Dipak P Ramji, Cardiff University, United Kingdom
Title : Global regulatory trends on the use of probiotics and prebiotics in foods and food supplements
David Pineda Ereno, DPE International Consulting, Belgium
Title : Biochemical profile and nutripotential glimpses of Terminalia arjuna bark extract
Suriyavathana Muthukrishnan, Periyar University, India